FDA panel rules that benefits of Endo’s Opana opioid no longer outweigh risks

An FDA advisory panel ruled yesterday that the benefits of Endo Pharmaceutical‘s opioid painkiller, Opana ER, no longer outweigh its risks. The painkiller has been linked to a 2015 HIV outbreak in Indiana after people addicted to opioids shared needles while injecting Opana.

The panel voted 18 to 8 that the drug’s benefits do not outweigh the risks, with some advisers concluded that the drug’s formulation seemed to encourage risky forms of injection drug abuse.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA panel rules that benefits of Endo’s Opana opioid no longer outweigh risks appeared first on MassDevice.

from MassDevice http://ift.tt/2nb1Emf